Abstract Details

Title A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity who are Treated With abobotulinumtoxin A

Topic Multiple Sclerosis

Presentation(s) P14 - Poster Session 14 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-003

Objective To determine the effect of Dysport® treatment on lower extremity spasticity, walking ability and quality of life (QoL) through 20 weeks of treatment

Background Spasticity-related muscle dysfunction is one of the most reported symptoms among patients with Multiple Sclerosis (MS). Previous studies have shown that Dysport® is effective as a treatment for upper limb spasticity, yet real-world evidence of the impact of Dysport® for patients with Multiple Sclerosis (MS) experiencing lower limb spasticity is very limited.

Design/Methods A sample of 28 patients with a confirmed diagnosis of MS over the age of 18 who met all protocol-defined inclusion criteria were recruited from the site’s clinical practice and enrolled into this longitudinal study. The first dose of Dysport® was administered on Day 1 via intramuscular injection, and efficacy assessments were performed (Modified Ashworth Scale [MAS], Multiple Sclerosis Impact Scale-29 [MSIS-29], Timed 25-Foot Walk Test [T25FW]) on Day 1, Week 4, Week 8, Week 12, Week 16 and Week 20. Data was analyzed using a repeated measures ANOVA.

Results 28 patients (mean age=52.8, 53.6% female) were enrolled in the study and received at least 1 treatment of Dysport® for symptoms of lower limb spasticity. Analysis showed that a contrast-coded linear trend was significant for MAS scores, and scores at Weeks 8-20 were significantly better than those at baseline. Similarly, contrast-coded linear trends for physical and psychological subscale scores of the MSIS-29 were significant, with improvement at Week 20. Analysis of T25FW scores did not show significance.

Conclusions Subjects treated with Dysport® showed clear improvements in muscle tone and reductions in physical and psychological subscale scores associated with MS disease burden through 20 weeks of study participation.

Authors/Disclosures
Salvatore Napoli, MD (Neurology Center of New England) PRESENTER	Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eisai. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for bristol myers. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bristol myers. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for serono. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for eisai. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Napoli has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for vaccine injury.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Sarah B. Cardoso (Neurology Center of New England P.C.)	Mrs. Cardoso has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��